Infutraze

Zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate, and manganese chloride tetrahydrate, the active ingredients in Infutraze, are trace element supplements presented as an intravenous solution for parenteral nutrition use. It supplies essential trace elements required for enzymatic activity and metabolic processes in patients receiving parenteral nutrition.

GNH USA supplies Infutraze as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Infutraze is used in parenteral nutrition to address trace element deficiencies.

Parenteral nutrition: provides essential zinc, copper, selenium, manganese and iodine for patients receiving intravenous feeding. Trace element deficiency: corrects low plasma levels of these trace elements. Critical illness: supports enzymatic functions and antioxidant defenses in critically ill patients. Preterm infants: supplies required trace elements for growth when enteral nutrition is insufficient.

Infutraze may be associated with infusion‑related reactions and rare systemic toxicities.

Common Side Effects: - Infusion site irritation or pain. - Transient metallic taste. - Mild nausea or vomiting. - Localized rash or pruritus.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction. - Copper or selenium toxicity presenting with hepatic or neurologic signs. - Severe electrolyte imbalance or metabolic acidosis.

Infutraze requires careful monitoring in specific clinical situations.

Renal impairment: monitor trace element levels and adjust therapy as needed. Hepatic dysfunction: assess for potential copper or selenium accumulation. Pregnancy: use only when the anticipated benefit outweighs potential risk. Infection or sepsis: observe for hypersensitivity during infusion. Compatibility: verify compatibility with other intravenous solutions before mixing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infutraze can interact with certain medications and supplements.

Major Interactions (Avoid): - Concurrent high‑dose copper supplements: risk of copper overload. - High‑concentration parenteral vitamin C: may cause precipitation. - Chelating agents such as EDTA: reduce availability of trace elements.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: iodine content may affect dosing. - Antioxidant therapies (e.g., N‑acetylcysteine): may alter selenium utilization. - Renal replacement therapy: can remove administered trace elements, requiring dose adjustment.